There has been some selling insider activity on Abbott Laboratories Common Stoc (NYSE:ABT) recently. Sr VP Daniel Gesua Sive Salvadori sold 815 shares at an average price of $41.71 on Mon the 26th. Salvadori now owns $2,459,889 of stock as reported to the SEC. Today Stephen R. Fussell, EVP disclosed the sale of 41,500 shares. The shares were purchased at an average price of $45.01. Fussell now owns $6,975,065 of the stock per the Form 4 SEC filing.
Michael J. Warmuth, EVP disclosed the sale of 26,800 shares of (ABT). The shares were sold on July 26th for an average price of $43.49. The EVP now owns $2,392,428 of the stock according to the SEC filing.
These funds have also shifted positions in (ABT). As of the end of the quarter Evercore Wealth Management, LLC had disposed of 7,712 shares trimming its stake by 8.4%. The value of the investment in Abbott Laboratories Common Stoc decreased from $3,861,000 to $3,325,000 a change of $536,000 for the reporting period. As of quarter end Macquarie Group Ltd had bought a total of 452,847 shares growing its holdings by 1,397.7%. The value of the investment in (ABT) went from $1,355,000 to $19,075,000 a change of 1,307.7% quarter over quarter.
As of the end of the quarter BNP Paribas Investment Partners S.A. had bought a total of 445 shares growing its position 0.7%. The value of the company’s investment in Abbott Laboratories Common Stoc went from $2,955,000 to $2,604,000 decreasing 11.9% quarter to quarter. As of quarter end Twin Tree Management, Lp had bought a total of 63,772 shares growing its position 1,623.5%. The value of the total investment in Abbott Laboratories Common Stoc increased from $163,000 to $3,040,000 increasing 1,765.0% since the last quarter.
September 13 investment analysts at Jefferies held the stock rating at “Buy” but lowered the price expectation from $49.00 to $48.00. On July 14 Jefferies kept the stock rating at “Buy” but moved up the price target to $49.00 from $45.00.
On June 21 the stock rating was upgraded from “” to “Buy” by analysts at Edward Jones. On June 14 Jefferies maintained a company rating of “Buy” but lowered the price target to $45.00 from $47.00.
On April 28 the company was downgraded to “Buy” from “” and a price target of $47.00 was set in a statement from Piper Jaffray. On March 15 Jefferies left the stock rating at “Buy” and raised the price expectation to $47.00 from $45.00.
The company is trading down by -0.09% since yesterday’s close of $42.33. Additionally Abbott Laboratories Common Stoc declared a dividend which was paid on Monday August 15th, 2016. The dividend payment was $0.260 per share for the quarter which is $1.04 annualized. This dividend represents a yeild of $2.47 which is the dividend as a percentage of the current share price. The ex-dividend date was set for Wednesday the 13th of July 2016.
It is trading at $42.29 just below $42.84, the stock’s 50 day moving average and just above the 200 day moving average of $41.26. The 50 day moving average was down $-0.55 and the 200 day average went up by +2.48%.
The P/E ratio is 27.91 and market cap is 62.17B.